Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.53 |
| ▸ | MMP3 | P08254 | 6/20 | 0.53 |
| ▸ | MMP7 | P09237 | 5/20 | 0.53 |
| ▸ | MMP13 | P45452 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23630361 | 0.86 | MMP1 (0.51) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630336 | 0.86 | MMP1 (0.53) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630312 | 0.83 | MMP1 (0.56) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630345 | 0.82 | MMP1 (0.58) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630587 | 0.82 | MMP1 (0.55) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630316 | 0.81 | MMP1 (0.54) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630326 | 0.81 | MMP1 (0.59) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630341 | 0.81 | MMP1 (0.57) | MMP1MMP3MMP7MMP13CA2 | |
| SCHEMBL23630441 | 0.78 | POLB (0.54) | LMNAMMP2 | |
| SCHEMBL23630366 | 0.78 | CA2 (0.50) | MMP1MMP3MMP7MMP13CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069886-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2023-03-09 | — | — | US | claimed |
| US-20230039836-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2023-02-09 | — | — | US | claimed |
| EP-4087650-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A1, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2022-11-16 | — | — | EP | claimed |
| EP-4087651-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A1, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2022-11-16 | — | — | EP | claimed |
| WO-2021141507-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | Uniwersytet Jagielloński (PL) | 2021-07-15 | — | — | WO | claimed |
| WO-2021141506-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A1, THEIR SYNTHESIS AND USE | Uniwersytet Jagielloński (PL) | 2021-07-15 | — | — | WO | claimed |
| US-20230069886-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2023-03-09 | — | — | US | disclosed |
| US-20230039836-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2023-02-09 | — | — | US | disclosed |
| EP-4087650-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A1, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2022-11-16 | — | — | EP | disclosed |
| EP-4087651-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A1, THEIR SYNTHESIS AND USE | UNIWERSYTET JAGIELLONSKI (PL) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021141506-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A1, THEIR SYNTHESIS AND USE | Uniwersytet Jagielloński (PL) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021141507-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | Uniwersytet Jagielloński (PL) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069886-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | PDIA3, PDIA5, PDIA6 | MMP1 3346/4885MMP3 1083/4885MMP7 1754/4885 |
| US-20230039836-A1 | AROMATIC SULPHONAMIDES DERIVATIVES THAT INHIBITS PDI A3, THEIR SYNTHESIS AND USE | PDIA3, PDIA5, PDIA6 | MMP1 2915/4885MMP3 1331/4885MMP7 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.